Professor, Medicine and Genetics Director Emeritus, Phase I Program
Oncology
Dr. Sridhar Mani, MD
Doctor Sridhar Mani, MD works in the field of Oncology. He graduated from Icahn School of Medicine at Mount Sinai. Icahn School of Medicine at Mount Sinai has a rank of 20 in research and a 62 in primary care Sridhar Mani has written publications. He has 77 publications published with PubMed. The lastest publication is: 'Acetylation of lysine 109 modulates pregnane X receptor DNA binding and transcriptional activity.'
Publications
- Acetylation of lysine 109 modulates pregnane X receptor DNA binding and transcriptional activity.
- AntiCancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.
- Diindolylmethane, a naturally occurring compound, induces CYP3A4 and MDR1 gene expression by activating human PXR.
- Plant flavonol isorhamnetin attenuates chemically induced inflammatory bowel disease via a PXR-dependent pathway.
- Understanding and Modulating Mammalian-Microbial Communication for Improved Human Health.
- Molecular Insights into Microbial β-Glucuronidase Inhibition to Abrogate CPT-11 Toxicity.
- Clinical outcome and prognostic markers for patients with gynecologic Malignancies in phase 1 clinical trials: A single institution experience from 1999 to 2010.
- Therapeutic Targeting of CPT-11 Induced Diarrhea: A Case For Prophylaxis.
- PXR antagonists and implication in drug metabolism.
- Methodologies to decipher the cell secretome.
- Pregnane xenobiotic receptor in Cancer pathogenesis and therapeutic response.
- Alleviation of gut inflammation by cdx2/pxr pathway in a mouse model of chemical colitis.
- Novel neurosensory testing in cancer patients treated with the epothilone B Analog, ixabepilone.
- Induction of CYP3A4 by vinblastine: Role of the nuclear receptor NR1I2.
- Modulation of irinotecan with cyclosporine: a phase II trial in advanced coloRectal cancer.
- A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.
- Synthesis of novel ketoconazole derivatives as inhibitors of the human Pregnane X Receptor (PXR; NR1I2; also termed SXR, PAR).
- Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced Pancreatic...
- Sixth International Congress on Shwachman-Diamond syndrome: from patients to genes and back.
- Pregnane X receptor activation induces FGF19-dependent tumor aggressiveness in humans and mice.
- Dose-escalating and pharmacological study of bortezomib in adult Cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Gr...
- In vivo and in vitro characterization of a first-in-class novel azole Analog that targets pregnane X receptor activation.
- Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the national Cancer institute organ dysfunction working group.
- Design, synthesis and biological evaluation of 2H-benzo[b][1,4] oxazine derivatives as hypoxia targeted compounds for Cancer therapeutics.
- Elucidating the 'Jekyll and Hyde' nature of PXR: the case for discovering antagonists or allosteric antagonists.
- Acetylation of pregnane X receptor protein determines selective function independent of ligand activation.
- Potent inhibition of rhabdoid tumor cells by combination of flavopiridol and 4OH-tamoxifen.
- Flavopiridol and trastuzumab synergistically inhibit proliferation of breast Cancer cells: association with selective cooperative inhibition of cyclin D1-dependent kin...
- Oxaliplatin: a review of evolving concepts.
- UCN-01 alters phosphorylation of Akt and GSK3beta and induces apoptosis in six independent human neuroblastoma cell lines.
- Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes.
- TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors.
- Phase I study of inhaled Doxorubicin for patients with metastatic tumors to the Lungs.
- Phase 1 dose escalation study of docetaxel with filgrastim support in patients with advanced solid tumors.
- Current approaches to novel therapeutics in pancreatic Cancer.
- A Phase II trial of fixed dose rate gemcitabine in patients with advanced biliary tree Carcinoma.
- Dose-escalating and pharmacological study of oxaliplatin in adult Cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working G...
- Phase I dose escalation study of KOS-1584, a novel epothilone, in patients with advanced solid tumors.
- Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group.
- Expanding the roles for pregnane X receptor in Cancer: proliferation and drug resistance in ovarian Cancer.
- Rhabdoid tumor growth is inhibited by flavopiridol.
- Orphan nuclear receptors as targets for drug development.
- A study of cytotoxic synergy of UCN-01 and flavopiridol in syngeneic pair of cell lines.
- The phytoestrogen coumestrol is a naturally occurring antagonist of the human pregnane X receptor.
- The clinical development of new mitotic inhibitors that stabilize the microtubule.
- Activated pregnenolone X-receptor is a target for ketoconazole and its Analogs.
- Tyrosine kinase inhibitors: a clinical perspective.
- Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer ...
- The BCL2-family of protein ligands as Cancer drugs: the next generation of therapeutics.
- Phase II trials of dolastatin-10 in advanced pancreaticobiliary Cancers.
- 9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenoCarcinomas of the stomach and gastroesophageal junction: A phase II t...
- Oxaliplatin pharmacokinetics and pharmacodynamics in adult Cancer patients with impaired renal function.
- Clinical and pharmacokinetic study evaluating the effect of food on the disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in patients with soli...
- Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors.
- Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin...
- Dose-escalating and pharmacologic study of oxaliplatin in adult Cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working G...
- A pilot study of edrecolomab (Panorex, 17-1A antibody) and capecitabine in patients with advanced or metastatic adenoCarcinoma.
- Alterations of chemotherapeutic pharmacokinetic profiles by drug-drug interactions.
- Activation of the steroid and xenobiotic receptor (human pregnane X receptor) by nontaxane microtubule-stabilizing agents.
- Validation of the pharmacodynamics of BMS-247550, an Analogue of epothilone B, during a phase I clinical study.
- Phase II study of paclitaxel plus the protein kinase C inhibitor bryostatin-1 in advanced pancreatic Carcinoma.
- Phase II study of mitomycin-C, adriamycin, cisplatin (MAP) and Bleomycin-CCNU in patients with advanced cancer of the Anal cAnal: An eastern cooperative oncology group...
- A phase 1 open-label, accelerated dose-escalation study of the hypoxia-activated prodrug AQ4N in patients with advanced Malignancies.
- Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors.
- The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of ixabepilone: a first in class epothilone B Analogue in late-phase clinical development.
- Phase I clinical trial of irinotecan with oral capecitabine in patients with gastrointestinal and other solid Malignancies.
- A phase II study of rebeccamycin Analog NSC 655649 in patients with metastatic colorectal cancer.
- A phase I safety and dose escalation trial of docetaxel combined with GEM231, a second generation antisense oligonucleotide targeting protein kinase A R1alpha in patie...
- A safety study of a mixed-backbone oligonucleotide (GEM231) targeting the type I regulatory subunit alpha of protein kinase A using a continuous infusion schedule in p...
- Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors.
- Pharmacokinetic and safety study of weekly irinotecan and oral capecitabine in patients with advanced solid Cancers.
- A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid Malignancies.
- The efficacy and safety of ixabepilone monotherapy in the treatment of Breast and gynecologic malignancies.
- Novel orphan nuclear receptors-coregulator interactions controlling anti-Cancer drug metabolism.
- Phase II trial of nolatrexed dihydrochloride [Thymitaq, AG 337] in patients with advanced hepatocellular Carcinoma.
- Erlotinib (Tarceva): a promising drug targeting epidermal growth factor receptor tyrosine kinase.
Schools
Mount Sinai School of Medicine
Yale New Haven Hospital
Conditions Treated
- Anal and Rectal Cancer
- Anemia
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- Brain Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
Yale-New Haven Hospital -
Yale New Haven Children's Center -
Icahn School of Medicine at Mount Sinai
Hospital
-
Montefiore Medical Center
Helpful Reviews
Similar Doctors
|
Dr. Cy A. Stein, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David J. Tamura, MD |
|
|
Dr. Zulfiqar Hussain, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jin S. Im, MD |
|
|
Dr. Jiahuai Tan, MD |